Rare Fusions, Real Targets: Ultraprecision Oncology in Lung Cancer.
Summary
This article highlights the significance of rare and ultrarare gene fusions, beyond established ones like ALK and ROS1, in lung cancer. It emphasizes that emerging fusions, involving receptor tyrosine kinases or their ligands, such as EGFR-SHC1, unveil novel mechanisms of oncogenic activation. These discoveries are propelling precision medicine towards an era of "ultraprecision" oncology, enabling increasingly individualized treatment strategies for cancer patients.
Analysis
The identification of rare and ultrarare fusions, such as EGFR-SHC1, represents a significant advancement for precision oncology in the clinic. These fusions act as predictive biomarkers, enabling the targeting of specific patient subpopulations with tailored therapies. Although the article does not mention specific clinical trials or levels of evidence, the discovery of new oncogenic targets justifies the development of Phase I/II trials to evaluate the efficacy of corresponding targeted therapies. The potential clinical impact is substantial, as it paves the way for more personalized treatments for patients who might otherwise lack targeted therapeutic options, with an estimated time to clinical impact of 3-5 years for the development and validation of new therapies.